<DOC>
	<DOC>NCT02906683</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of TAS-303 in female patients with stress urinary incontinence.</brief_summary>
	<brief_title>Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence</brief_title>
	<detailed_description>The main purpose of this study is to assess the efficacy of TAS-303 for 8 weeks in female patients with stress urinary incontinence (SUI) compared with placebo as measured by the percent change in incontinence episode frequency (IEF) from baseline.</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence, Stress</mesh_term>
	<criteria>Patient has symptoms of Stress Urinary Incontinence (SUI) for at least 12 weeks prior to study entry Patient has at least 1 incontinence episodes per day, and urinary diurnal frequency of 10 or less per day and nocturia of 2 or less per day. Patient is positive in 1hour pad weight test Patient has predominant or primary urge incontinence according to investigator judgment Patient had a prior surgical SUI treatment Patient is diagnosed stageII or more of Pelvic Organ Prolapse Patient has symptoms of Urinary tract infection (UTI) Patient is positive pregnancy test Patient has on physical examination, neurological and/or vaginal examination results which, in the opinion of the investigator, should exclude the subject.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Urinary Incontinence</keyword>
	<keyword>Urinary Incontinence, Stress</keyword>
	<keyword>Lower Urinary Tract Symptoms</keyword>
</DOC>